RNA Analysis Market Size, Share & Industry Analysis, By Product Type (Reagents & Consumables, Instruments, and Software & Services), By Technology (PCR-based Technologies, Sequencing-based Technologies, Microarray-based Technologies, RNA interference (RNAi)-based Techniques, & Others), By Application (Drug Discovery & Development, Clinical Diagnostics, Cell Biology Research, Toxicogenomics, Comparative Transcriptomics, & Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Clinical & Diagnostic Laboratories, & Others), & Regional Forecast, 2026-2034

The global RNA analysis market size was valued at USD 9.64 billion in 2025. The market is projected to grow from USD 10.43 billion in 2026 to USD 19.03 billion by 2032, exhibiting a CAGR of 7.80% during the forecast period.

RNA analysis encompasses a wide range of products for the study and quantification of RNA molecules, including mRNA, miRNA, and other non-coding RNAs. These are useful for understanding gene expression, regulation, and cellular functions. The rising adoption of molecular diagnostics and drug development for early diagnosis and personalized treatment approaches is boosting market growth.

The increasing prevalence of cancer, genetic disorders, and infectious diseases has heightened the adoption of RNA analysis for diagnosis and treatment to propel the growth of the global RNA analysis market.

• For instance, in October 2025, Novartis acquired Avidity Biosciences, Inc. to incorporate the company’s new class of therapeutics, RNA therapeutics, for strengthening its late-stage neuroscience pipeline.

The market encompasses several major players, with Thermo Fisher Scientific Inc. and Illumina Inc. at the forefront. The robust portfolio and strategic activities support the dominance of these companies in the market.

MARKET DYNAMICS

MARKET DRIVERS

Shift toward Precision Medicine and Oncology Genomics to Propel Market Growth

The key driver propelling the RNA analysis market is the shift toward precision medicine and oncology genomics. The increasing prevalence of genetic diseases and cancer is prompting patients and healthcare providers toward effective treatment options based on the genetic profile and tumor biology.

RNA analysis aids early diagnosis and prognosis of cancer, driving the development of RNA based targeted therapies, thereby improving treatment efficacy while reducing adverse effects.

As research in oncology genomics continues to expand, key market players are increasingly focused on offering innovative RNA-based diagnostic and therapeutic tools. Overall, such advancements are significantly accelerating the growth of the global RNA analysis market.

• For instance, in September 2025, Tempus AI, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the RNA-based Tempus xR IVD device. The xR IVD supports drug development programs for solid tumors and hematologic malignancies.

MARKET RESTRAINTS

Product Recalls of RNA Analysis Kits to Restrict Market Growth

Product recall involving instruments and devices used for RNA Analysis hampers the brand image and consumers' trust, thus restricting market growth. Recall raise concern about safety and quality standards, leading to decreased demand from laboratories and research institutions. Such factors restrict the product sales and RNA analysis market growth.

• For instance, in April 2023, the FDA issued a warning to healthcare providers and labs about a cybersecurity vulnerability in the Universal Copy Service (UCS) software used by various Illumina sequencing devices, including MiSeqDx, NextSeq series, iScan, iSeq 100, MiniSeq, and NovaSeq 6000. These devices are used for clinical genetic diagnostics or research, where unauthorized attackers can remotely control the devices, modify settings or data, or compromise genomic results.

MARKET OPPORTUNITIES

Increasing Prevalence Of Neurological Diseases to Create Lucrative Growth Opportunities

The increasing prevalence of neurological diseases, infectious diseases, and cardiovascular conditions, along with the rising demand for precision medicine and diagnosis for such diseases, boosts the demand for the expansion of RNA sequencing and analysis technologies across a broader range of diseases.

Additionally, expanding into these applications is fostering innovation in molecular diagnostics and RNA therapeutics, fueling long-term growth in the rapidly evolving landscape of molecular medicine.

• For instance, in December 2025, Circular Genomics, Inc., a developer of circular RNA-based precision medicine tools for neurology and psychiatry, secured USD 15.0 million in funding to accelerate the clinical development and commercialization of a circRNA biomarker platform for the early detection of Alzheimer's disease (AD).

RNA ANALYSIS MARKET TRENDS

Development of Single-cell and Spatial Transcriptomics is a Key Market Trend

Currently available RNA analysis platforms often struggle with high costs, complex workflows, or insufficient sensitivity to detect rare transcripts. Single-cell and spatial transcriptomics address these gaps by offering higher throughput, enhanced spatial resolution, and seamless integration of multi-omics. This allows researchers to obtain more accurate, detailed, and scalable insights into cellular functions and tissue architecture.

• For instance, in March 2025, Singleron Biotechnologies launched MobiuSCOPE, a single-cell RNA sequencing kit that offers full-length transcript analysis using standard short-read sequencing. It captures detailed transcript features, such as alternative splicing, gene fusions, and SNPs, by providing complete coverage while reducing the bias common in traditional methods. This enhances the detection of cellular heterogeneity, novel mechanisms, biomarkers, and therapeutic targets at single-cell resolution.

MARKET CHALLENGES

Shortage of Skilled Personnel to Challenge Market Growth

A key challenge in the RNA analysis market is the shortage of skilled bioinformaticians and computational biologists capable of designing reliable workflows, managing pipelines, and interpreting complex data.

As a result, many labs that lack in-house expertise are forced to outsource analyses, increasing the overall cost, which hampers adoption and undermines confidence in the results.

Download Free sample to learn more about this report.

Segmentation Analysis

By Product Type

Increasing Product Launches of Reagents & Consumables Propelled the Segment’s Growth

The product type segment is divided into reagents & consumables, software & services, and instruments.

To know how our report can help streamline your business, Speak to Analyst

The reagents & consumables segment held a dominant portion of the RNA analysis market share in 2025. The rising research and development activities, along with an increased focus on genomic research, have boosted the segment’s growth in the market. Additionally, increasing new product launches will propel the segment’s growth.

• For instance, in May 2024, QIAGEN launched the QIAseq Multimodal DNA/RNA Library Kit. The kit enables the seamless preparation of DNA and RNA libraries for next-generation sequencing NGS, such as whole-genome sequencing (WGS) and whole-transcriptome sequencing (WTS), from a single sample.

The instruments segment is expected to grow at a CAGR of 6.87% over the forecast period. 

By Technology

Increasing Adoption of Sequencing-based Technologies Boosted the Segment’s Growth

In terms of technology, the market is categorized into PCR-based technologies, sequencing-based technologies, microarray-based technologies, RNA interference (RNAi)-based techniques, and others. The sequencing-based technologies segment accounted for the largest portion of the market. In 2025, the segment is anticipated to dominate with a 38.25% share. The maximum share of the segment is due to its increasing adoption of these technologies for RNA research and the rising introduction of new sequencing technology for genomic applications.

• For instance, in February 2025, Roche launched Sequencing by Expansion (SBX) technology, a breakthrough in next-generation sequencing (NGS). This method efficiently sequences DNA and RNA by converting genetic material into a longer surrogate called an Xpandomer, which offers a flexible, high-throughput, and scalable solution for various genomic applications.

The PCR-based technologies segment is expected to grow at a CAGR of 3.85% over the forecast period.  

By Application

Increasing Prevalence of Genetic Diseases Boosted the Drug Discovery & Development Segments' Growth

Based on application, the market is segmented into drug discovery & development, clinical diagnostics, cell biology research, toxicogenomics, comparative transcriptomics, and others.

The drug discovery & development segment held the dominating position in 2025. The drug discovery & development segment held a 29.80% share in 2025. The increasing prevalence of genetic diseases, cancer, and neurological conditions, along with the rising demand for personalized medicine, is expected to boost the segment’s growth in the market.

• For instance, in November 2025, Arrowhead Pharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine. A protein assay was used in the development of this medicine. This drug reduces triglycerides in adults with familial chylomicronemia syndrome (FCS).

The clinical diagnostics segment is poised for growth, with a forecasted rate of 9.40% in the global RNA analysis market during the forecast period.

By End User

Increasing Funding Activities and Rising Research Programs to Boost the Pharmaceutical & Biotechnology Companies Segment

Based on end user, the market is segmented into pharmaceutical & biotechnology companies

academic & research institutes, CROs & CDMOs, and others. In 2025, the pharmaceutical & biotechnology companies segment is expected to witness a leading growth trajectory. The segment is set to hold 38.6% share in 2025.  The rising adoption of products and services for RNA analysis to develop new therapeutics for various diseases is expected to boost the adoption of these products in these settings. Additionally, increasing funding activities to develop RNA therapeutics is contributing to the segment's growth in the market.

• For instance, in August 2023, ADARx Pharmaceuticals secured USD 200 million in financing. The funding was used to advance ADARx clinical programs, including ADX-324 and ADX-038. ADX-324 for the treatment of hereditary angioedema, a rare genetic disease.

The academic & research institutes segment is projected to grow at a CAGR of 6.44% during the study period.

RNA Analysis Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2025, valued at USD 4.99 billion, and also maintained its leading share in 2026 with USD 5.41 billion. The dominance of the regions in the market is driven by the presence of key players with advanced product offerings and a rising focus on investment in the RNA analysis market for research and development. In 2025, the U.S. market is estimated to reach USD 4.75 billion.

The U.S. is expected to dominate the North America region's market. The rising presence of proteomic research, combined with adequate funding and a supportive research environment, is boosting the country’s growth in the market.

• In May 2023, Twist Bioscience and CeGaT GmbH launched the Twist Alliance CeGaT RNA Fusion Panel, a new tool for oncology research. This panel detects RNA fusions and analyzes transcript variants, which are genetic rearrangements common in cancer.

Europe and the Asia Pacific are expected to experience notable growth in the coming years. During the forecast period, the European region is projected to record a growth rate of 7.59%, the second-highest among all regions, and reach a valuation of USD 2.49 billion in the RNA analysis market by 2025. Rising molecular biology research and increasing drug development for chronic diseases and genetic diseases, with active government support to boost market growth in the region. Backed by these factors, countries including the U.K. are expected to record the valuation of USD 0.54 billion, Germany to record USD 0.50 billion, and France to record USD 0.40 billion in 2025. After Europe, the Asia Pacific market is estimated to reach USD 1.53 billion by 2025 and secure the position of the third-largest region in the market. In the region, India and China are both estimated to reach USD 0.28 billion and USD 0.27 billion, respectively, in 2025.

The Latin America and Middle East & Africa regions would witness a moderate growth in the market over the forecast period. The Latin America market in 2025 is expected to reach a valuation of USD 0.39 billion. Increasing focus of key players to shift their presence in the region to boost market growth, but at a slower rate. In the Middle East and Africa MEA, the GCC is set to reach a value of USD 0.11 billion by 2025.

COMPETITIVE LANDSCAPE

Key Industry Players

Expansion of Product Offering and Strong Research and Development Activities to Maintain Their Market Position

The global RNA analysis market exhibits a fragmented structure, with a large number of companies actively operating worldwide. These players have a robust product portfolio, backed by strong research and development capabilities.

Thermo Fisher Scientific Inc., Illumina Inc., and Agilent are among the leading companies in the industry. Their extensive product portfolios and ongoing new product launches are anticipated to strengthen their market positions.

Additionally, other significant players, such as Bio-Rad Laboratories and Bruker, are also prominent in the market. These companies are concentrating on providing a diverse range of assay kits and reagents to expand their market presence.

LIST OF KEY RNA ANALYSIS COMPANIES PROFILED

• Thermo Fisher Scientific Inc. (U.S.)
• Illumina Inc. (U.S.)
• 10x Genomics (U.S.)
• QIAGEN (Netherlands)
• Agilent (U.S.)
• Bruker (U.S.)
• Bio-Rad Laboratories (U.S.)
• Hoffmann-La Roche Ltd (Switzerland)

KEY INDUSTRY DEVELOPMENTS

• October 2025: Lexogen launched the miRVEL Profiling Small RNA-Seq Library Prep Kit to facilitate small RNA research.
• October 2025: Plasmidsaurus, a premier Sequencing as a Service provider, announced the launch of its new RNA-Seq offering by extending its speed, convenience, and insightful analysis capabilities to gene expression studies.
• May 2025: TriLink BioTechnologies started donating mRNA synthesis kits to top academic labs across the U.S. and Europe.
• January 2025: Leica Biosystems collaborated with Molecular Instruments to enable fully integrated RNA-ISH using the BOND RX and BOND RXm research staining systems.
• June 2024: Bio-Rad Laboratories, Inc. launched the ddSEQTM Single-Cell 3' RNA-Seq Kit and complementary Omnition v1.1 analysis software for single-cell transcriptome and gene expression research.

REPORT COVERAGE

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation